Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trialBrian I. Rini, Thomas Powles, V.P. Stus et al.|Nature Medicine|2025Cited by 44